

LISTING OF CLAIMS

1.-68. **(Cancelled)**

69. **(Previously presented)** A method for limiting the mitogenic activity of proliferating epithelial cells in a mammal in need thereof, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with said epithelial cells, wherein said morphogen:

- (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5;
- (ii) is not TGF β 2; and
- (iii) is capable of inhibiting lesion formation in an *in vivo* oral mucositis assay, so as to thereby limit the mitogenic activity of said cells in said mammal.

70. **(Previously presented)** The method of claim 69, wherein said epithelial cells are epidermal skin cells.

71. **(Previously presented)** The method of claim 70, wherein proliferation of said cells is associated with psoriasis.

72. **(Previously presented)** A method for inhibiting scar tissue formation at a site of tissue damage in a mammal, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with cells at a site of tissue damage in the mammal, wherein said morphogen:

- (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5;
- (ii) is not TGF β 2; and
- (iii) is capable of inhibiting lesion formation in an *in vivo* oral mucositis assay, so as to thereby inhibit scar tissue formation at a site of tissue damage in said mammal.

73. **(Cancelled)**